Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | HINT1 | P49773 | 3/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 9/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443133 | 0.92 | NT5E (0.76) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL22001502 | 0.87 | NT5E (0.69) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21184238 | 0.87 | NT5E (0.71) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21184245 | 0.86 | TGM2 (0.66) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21162739 | 0.86 | TGM2 (0.66) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL28966852 | 0.85 | NT5E (0.73) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21184319 | 0.85 | TGM2 (0.64) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21184381 | 0.85 | TGM2 (0.64) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL21171852 | 0.85 | NT5E (0.71) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL18648315 | 0.85 | NT5E (0.71) | NT5ETGM2HINT1IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | NT5E 572/4885TGM2 3563/4885HINT1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.